Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1516 to 1530 of 7707 results

  1. Discussing and planning medicines support

    A quick guide for home care managers providing medicines support.

    Social care quick guide
    Published
    25 May 2022

  2. Building independence through planning for transition

    NICE social care quick guide - building independence through planning for transition.

    Social care quick guide
    Published
    25 May 2022

  3. Good practice in safeguarding training

    A quick guide to good practice in safeguarding training

    Social care quick guide
    Published
    21 July 2022

  4. Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)

    Evidence-based recommendations on aripiprazole for treating schizophrenia in young people aged 15 to 17.

    Technology appraisal guidance
    Published
    26 January 2011
    View recommendations

    Sections for TA213

  5. Tezepelumab for treating severe asthma (TA880)

    Evidence-based recommendations on tezepelumab (Tezspire) for treating severe asthma in people 12 years and over.

    Technology appraisal guidance
    Published
    20 April 2023
    View recommendations

    Sections for TA880

  6. Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

    Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.

    Technology appraisal guidance
    Published
    23 February 2011
    View recommendations

    Sections for TA214

  7. Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)

    Evidence-based recommendations on bevacizumab gamma (Lytenava) for treating wet age-related macular degeneration in adults.

    Technology appraisal guidance
    Published
    4 December 2024
    View recommendations

    Sections for TA1022

  8. Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA1021)

    Evidence-based recommendations on crizotinib (Xalkori) for treating ROS1-positive advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    4 December 2024
    View recommendations

    Sections for TA1021

  9. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

    Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.

    Technology appraisal guidance
    Last updated
    20 June 2018
    View recommendations

    Sections for TA217

  10. Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (TA218)

    Evidence-based recommendations on azacitidine (Vidaza) for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    23 March 2011
    View recommendations

    Sections for TA218

  11. Ublituximab for treating relapsing multiple sclerosis (TA1025)

    Evidence-based recommendations on ublituximab (Briumvi) for treating relapsing multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    18 December 2024
    View recommendations

    Sections for TA1025

  12. Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)

    Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.

    Technology appraisal guidance
    Published
    22 August 2012
    View recommendations

    Sections for TA263

  13. Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)

    Evidence-based recommendations on pazopanib (Votrient) for previously untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Last updated
    1 August 2013
    View recommendations

    Sections for TA215

  14. Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)

    Evidence-based recommendations on bendamustine for treating chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    23 February 2011
    View recommendations

    Sections for TA216

  15. Golimumab for the treatment of psoriatic arthritis (TA220)

    Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    27 April 2011
    View recommendations

    Sections for TA220